U.S., May 9 -- ClinicalTrials.gov registry received information related to the study (NCT07575308) titled 'HMBeacon: A Phase 2 Study to Evaluate ALN-6400 in Adult and Adolescent Female Patients With VWD and HMB' on May 04.
Brief Summary: The purpose of this study is to evaluate the safety, tolerability, efficacy, and pharmacodynamics (PD) of multiple doses of ALN-6400 in adult and adolescent patients with VWD and HMB
Study Start Date: May 05
Study Type: INTERVENTIONAL
Condition:
Von Willebrand Disease (VWD)
Heavy Menstrual Bleeding (HMB)
Intervention:
DRUG: ALN-6400
ALN-6400 will be administered subcutaneously (SC).
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Alnylam Pharmaceuticals
Published by HT Digital Content Services wi...